Novo Nordisk A/S (NVO) vs Novartis (NVS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Novartis (NVS) has outperformed Novo Nordisk A/S (NVO) over the past year, gaining 18.2% versus a loss of 20.6%. Over five years, NVS leads with a +86.5% price change compared with -30.1% for NVO. Novartis is the larger company by market cap ($284.18 billion vs $166.69 billion), about 1.7 times the size.
On valuation, Novo Nordisk A/S trades at a lower forward P/E (10.8x vs 15.1x for Novartis). Novo Nordisk A/S offers the higher dividend yield (30.94% vs 3.10%).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NVO | NVS |
|---|---|---|
| Share price | $37.82 | $150.47 |
| Market cap | $166.69B | $284.18B |
| 1-day change | -2.70% | -0.50% |
| YTD return | -25.67% | +9.14% |
| 1-year return | -20.60% | +18.19% |
| 5-year return | -30.07% | +86.46% |
| P/E ratio (TTM) | 9.55 | 28.72 |
| Forward P/E | 10.77 | 15.15 |
| EPS (TTM) | $3.96 | $5.24 |
| Dividend yield | 30.94% | 3.10% |
| Annual dividend | $11.70 | $4.67 |
| Net income (latest FY) | — | $13.98B |
| 52-week high | $64.16 | $170.46 |
| 52-week low | $35.12 | $126.50 |
| Distance from 52-week high | -41.05% | -11.73% |
| Analyst consensus | hold | hold |
| Avg. price target upside | +20.28% | +4.41% |
| Average volume | 12.59M | 2.18M |
| Shares outstanding | 3.33B | 1.89B |
| Employees | 68,794 | 75,267 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- NVS has outperformed NVO by 38.8 percentage points over the past year.
- Novartis trades at a higher earnings multiple (28.7x vs 9.6x trailing P/E).
- Novo Nordisk A/S offers a meaningfully higher dividend yield (30.94% vs 3.10%).
About Novo Nordisk A/S
NVO stock →Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 68,794 employees
About Novartis
NVS stock →Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure; Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6; Promacta/Revolade for immune thrombocytopenia (ITP), thrombocytopenia, and aplastic anemia patients; Tafinlar+Mekinist, an oral combination therapy to treat cancer patients; and Jakavi for treating myelofibrosis, polycythemia vera, and acute or chronic graftversushost disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 75,267 employees
NVO vs NVS FAQ
Which is bigger, Novo Nordisk A/S or Novartis?
Novartis (NVS) is larger, with a market capitalization of $284.18B compared with $166.69B for Novo Nordisk A/S (NVO).
Which stock has performed better over the past year, NVO or NVS?
NVS returned +18.19% over the past 12 months, compared with -20.60% for NVO (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, NVO or NVS?
NVO has the lower trailing P/E at 9.6, versus 28.7 for NVS. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Which pays a higher dividend, Novo Nordisk A/S or Novartis?
Novo Nordisk A/S has the higher yield at 30.94%, compared with 3.10% for Novartis.
Are Novo Nordisk A/S and Novartis in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.